MAIA Biotechnology, Inc. (MAIA) - 10-Q Summary
Business Context and Reporting Period
Company: MAIA Biotechnology, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: MAIA is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, with a lead asset, ateganosine (THIO), currently in Phase 2 trials for Non-Small Cell Lung Cancer (NSCLC). The company operates as a single segment focused on oncology drug development.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(8,903,189) | $(18,767,410) | $(19,682,718) |
| Loss Per Share (Basic/Diluted) | $(0.27) | $(0.62) | $(0.93) |
| Operating Expenses | $9,360,926 | $19,952,414 | $11,952,606 |
| Cash and Cash Equivalents (End of Period) | $10,891,736 | $10,891,736 | $8,690,784 |
| Working Capital | $1,760,492 | $1,760,492 | $6,322,441 |
| Accumulated Deficit | $(106,002,244) | $(106,002,244) | $(83,662,895) |
Debt & Liquidity: The company has no long-term debt. Total liabilities are $11,740,351, primarily consisting of current liabilities ($9,994,444) and a warrant liability ($1,745,907). Cash flow from operations was negative $11.8 million for the nine months ended September 30, 2025, offset by $13.1 million in financing activities.
Material Changes vs. Prior Period
- Operating Expenses: Increased significantly year-over-year. For the nine months ended September 30, 2025, total operating expenses rose 67% to $19.95 million from $11.95 million in the prior year period.
- Research & Development (R&D): Increased 80% to $12.67 million, driven by increased scientific and clinical research costs.
- General & Administrative (G&A): Increased 48% to $7.29 million, largely due to higher investor relations costs and professional fees.
- Net Loss: The net loss for the nine months ended September 30, 2025, decreased slightly by 5% compared to the prior year, primarily due to a favorable change in the fair value of warrant liabilities (a gain of $944,698 in 2025 vs. a loss of $8.0 million in 2024).
- Capital Structure: The company raised approximately $12.7 million in gross proceeds during the nine months ended September 30, 2025, through a combination of At-The-Market (ATM) offerings and multiple private placement rounds.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Clinical Progress: MAIA continues to advance its lead candidate, ateganosine. The company received FDA Fast Track designation for NSCLC in July 2025. Positive updated data from the THIO-101 Phase 2 trial showed a median overall survival of 17.8 months. The company plans to initiate a Phase 3 pivotal trial (THIO-104) in 2025.
- Strategic Shift (Digital Assets): On October 6, 2025, the Board adopted a Digital Asset Treasury Plan (DATP), authorizing the allocation of up to 90% of corporate treasury reserves to acquire Bitcoin, Ether, and USD Coin. As of the filing date, no purchases had been executed.
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for one year following the issuance of these financial statements. The company has incurred recurring losses and will require additional equity or debt financing to meet future working capital needs.
Risks & Contingencies:
- Liquidity Risk: Dependence on continued capital raises to fund operations and clinical trials.
- Digital Asset Risk: The new DATP exposes the company to significant market volatility, regulatory uncertainty regarding the classification of digital assets as securities, and cybersecurity risks.
- Regulatory Risk: No assurance that clinical trials will succeed or that regulatory approval will be granted for ateganosine.
Investor Verification Checklist
- Capital Adequacy: Verify the timeline and certainty of future financing given the "substantial doubt" going concern warning and the high burn rate ($11.8M operating cash outflow YTD).
- Digital Asset Strategy: Review the specific implementation details of the Digital Asset Treasury Plan (DATP), including custody arrangements and the potential impact on the company's balance sheet volatility.
- Clinical Milestones: Confirm the enrollment status and data readout dates for the THIO-101 Phase 2 trial and the initiation timeline for the THIO-104 Phase 3 trial.
- Dilution: Assess the impact of recent and planned equity issuances (ATM and private placements) on existing shareholder ownership, noting the significant increase in shares outstanding (from ~26M to ~34.5M in 9 months).
- Warrant Liability: Monitor the fair value of the remaining warrant liability ($1.75M) and its potential impact on future earnings volatility.